Apmonia Therapeutics laureate from EIC accelerator program
Apmonia Therapeutics will receive €2.5 million in funding and €7 million in equity investment from the European Innovation Council (EIC) [...]
HEPHAISTOS secures €10.3 M to reach the clinical stage
HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M [...]
PDC*line Pharma completes enrolment of four cohorts of patients in PDC-LUNG-101 phase I/II clinical trial
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today [...]
In’CaRe: Call for projects in Oncology and Hematology
Cancers are still a major public health issue. Promoting innovation in oncology in France therefore remains a priority. AstraZeneca demonstrates [...]
The Amgen France Fund for Science and Humans launches its 4th call for projects
Following the success of previous calls for projects, the Amgen France Fund for Science and Humans is launching a fourth [...]
Newsletter MATWIN June 2023
Download here the latest MATWIN newsletter :
MATWIN – PSCC partnership – Interview Benjamin Garel
Interview of Benjamin GAREL, General Manager of Paris Saclay Cancer Cluster who signed a partnership with MATWIN last May 2023 [...]
MATWIN is hiring a R&D Project Manager (Oncology)
You dream of taking part in an exciting and meaningful adventure, of joining a start-up like team willing to accelerate [...]
MATWIN BOARD MEETING 2023
A unique committee in Europe, the MATWIN Board is made up of around twenty international R&D decision-makers from the World [...]
PR: MATWIN highlights about thirty innovative projects to tackle cancer
Download the press release:
PR: MATWIN and the Paris Saclay Cancer Cluster join their forces to accelerate innovation in the fight against cancer
MATWIN and the Paris Saclay Cancer Cluster join their forces to accelerate innovation in the fight against cancer. This collaboration [...]
2023 Horizon Europe call to support the EU Cancer Mission
Apply for the 2023 HorizonEU call under the EU Cancer Mission to improve cancer research, prevention, diagnostics and patients' quality [...]
Call for projects – PANCREAS 2023
As a continuation of its scientific strategy initiated in 2022 to support research on pancreatic cancer, and following the success [...]
Launch of the 12th Bristol Myers Squibb Foundation call for proposals for research in immuno-oncology
The Bristol Myers Squibb Foundation announces the launch of its 12th call for proposals for research in immune oncology, open [...]
BIPER THERAPEUTICS RAISES €1.25 MILLION
BiPer Therapeutics, awarded during OUI (Oncology Upward Investment) 2021 edition of MEET2WIN raises €1.25 million in seed funding to develop [...]
Partnership MATWIN and European Health Investor Network
MATWIN and the European Health Investor Network announce their new partnership to maximise the investment potential of innovative startups in [...]
Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma
Genoscience Pharma, supported by MATWIN in 2021, receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma. Download the [...]
First US leukemia patient dosed with investigational SMART101 cell therapy
Smart Immune announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection [...]
Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”
Brenus Pharma, a biotech company specialized in the development of new generations of allogeneic cell-based immunotherapies supported by MATWIN in [...]
Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial
Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma in combination with an immune [...]
EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
EverImmune supported by MATWIN in 2022 and interviewed by the MATWIN Board launches a phase I clinical trial for its [...]
MPC Therapeutics announces completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.
MPC Therapeutics supported by MATWIN in 2022 and awarded by MATWIN International Board for the "Best Technological Innovation" announces completion of [...]
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancersSmart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
Smart Immune supported by MATWIN in 2022 and awarded “ Best Therapeutic Innovation” by MATWIN International Board launches a Phase I/II trial in adults with [...]
Interview with Karine ROSSIGNOL, CEO Smart-Immune, MATWIN 2022 winner “Best therapeutic innovation”
Introduce us SMARTIMMUNE in a few words Smart Immune, a clinical-stage biotechnology company, is developing a cell therapy platform called [...]
International Cancer Cluster Showcase 2022
MATWIN is a partner of the 10th International Cancer Cluster Showcase, international event showcase of innovation in oncology traditionally backed by the [...]